You are here

Article Text

Article menu
Download PDFPDF
Miscellanea
Journal club
Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis
  1. Rachel Mackley
  1. Correspondence to Rachel Mackley, Respiratory ST4, Royal Preston Hospital, Sharoe Green Lane, Fulwood, Preston, PR2 9HT, UK; rachel.mackley{at}doctors.org.uk

https://doi.org/10.1136/thoraxjnl-2012-202848

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    This randomised, double-blind placebo control trial from New Zealand looked at the use of azithromycin in non-cystic fibrosis bronchiectasis and aimed to assess its effect on exacerbation frequency, lung function and health-related quality of life.

    The trial enrolled 141 participants and randomly assigned them to receive either azithromycin 500 mg three times a week for 6 months, or placebo, …

    View Full Text

    Footnotes

      • Wong C, Jayaram L, Karalus N, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-control trial. The Lancet 2012;380:660–7.

    • Competing interests None.

    • Provenance and peer review Not commissioned; externally peer reviewed.